Skip to content

Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria

Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria: Management by General Practitioners in Bas-Rhin.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06910878
Acronym
EBLSE
Enrollment
100
Registered
2025-04-04
Start date
2024-10-24
Completion date
2025-12-24
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Keywords

Urinary Tract Infections, Beta-Lactamase, Enterobacteriaceae

Brief summary

Urinary tract infections (UTIs) are one of the most common pathologies encountered in general practice. However, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) pose a particular challenge due to their increased resistance to many commonly used antibiotics. The aim of this thesis is to study the management of such infections by general practitioners in Bas-Rhin and to suggest possible avenues for improvement.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (≥18 years old) * Subject with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024 * Subject not objecting, after being informed, to the reuse of their data for the purposes of this research. * The subject's primary care physician agreeing to participate in the study

Exclusion criteria

* Subject and/or their primary care physician having expressed their opposition to participating in the study * Subject under legal protection * Subject under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIsUp to 1 yearPrescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs by general practitioners compared to current health authority recommendations

Countries

France

Contacts

Primary ContactYves HANSMANN, MD, PhD
yves.hansmann@chru-strasbourg.fr33 3 69 55 09 78

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026